Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
8,708 total articles
Bandwidth (BAND) is ripping higher today on heavy volume as the market begins to reward improving enterprise adoption and cash flow. The setup is a tactical swing trade: buy into strength at the market, protect with a tight stop below recent intraday lows, and target a materially higher multiple as adoption and partnership contribution become visib…
Eagle Materials (EXP) looks ready for an upgrade. Record revenue, strong free cash flow and healthy returns combine with attractive earnings multiple and improving technicals. This trade idea outlines a mid‑term long with clear entry at $205.00, stop at $195.00 and a $250.00 target over the next 45 trading days.
Royal Caribbean (RCL) looks set to keep recovering its pricing power despite near-term oil volatility. The company trades at a reasonable P/E (~16x) with strong ROE (42.5%) and positive free cash flow. We present a mid-term trade: entry $265.00, target $320.00, stop $242.00, horizon mid term (45 trading days).
Amazon's valuation already prices it as a cash-generative tech platform, but accelerating AI adoption across enterprises - and clear signs AWS can convert that demand into revenue - make a tactical long attractive. Entry at $265, target $320, stop $245; horizon: long term (180 trading days).
eBay looks like a constructive buy here: the company combines high returns on equity, steady free cash flow generation and shareholder-friendly buybacks with a refreshed growth runway (Depop acquisition and focus on collectibles). At roughly $104 per share, the stock trades at mid-20s P/E and an EV/EBITDA below 19, offering a favorable risk-reward …
Zenas BioPharma is a high-conviction long because management has secured new financing, is preparing a BLA filing for obexelimab, and expects Phase 2 lupus data by year-end 2026. The market has punished the stock after a disappointing IgG4-RD Phase 3 readout, leaving upside if obexelimab shows meaningful activity in SLE or if the FDA engagement aro…
Nuvalent is a clinical-stage precision oncology company with two lead kinase programs that have near-term regulatory and pivotal catalysts in 2026. The stock trades at about $99.35 with a market cap near $7.85B and roughly $2.87B in cash on the balance sheet. This trade idea is a directional long into upcoming FDA decisions and program readouts, wi…
Meta beat Q1 expectations with 33% revenue growth to $56.31B and sharply higher EPS, yet shares plunged after management raised 2026 capex to $125-145B. That capex is largely AI infrastructure spending that should expand long-term TAM and protect margins vs. competitors. This trade idea buys the selloff with a clear entry, stop and target aligned t…
Cullinan Therapeutics is a clinical-stage oncology and immuno-oncology company trading at roughly $790M market value while sitting on a large cash position. Positive pivotal data in its zipalertinib program and multiple clinical readouts set up a potential 2027 FDA catalyst. For traders willing to accept clinical binary risk, a mid-term long (45 tr…
Svenska Handelsbanken has the balance-sheet profile and business mix to weather renewed macro volatility. This trade idea recommends a long position with a clearly defined entry at $9.00, a stop at $7.80 and a primary target of $11.25 over a 180-trading-day horizon, aiming to capture a re-rating tied to stable profitability, steady dividend support…
QXO recently agreed to buy TopBuild for $17 billion, creating a much larger building-products distributor. The market punished QXO shares on dilution and leverage concerns, but the combined company will generate roughly $18 billion in revenue and target $300 million in synergies by 2030. With a market cap near $14.36B and free cash flow of $183.2M,…
Solid Power is showing incremental progress toward commercializing solid-state EV cells. Balance-sheet liquidity, a design that targets factory compatibility, and improving market sentiment create a tactical buying opportunity. This trade lays out an entry at $3.47, a $5.25 target and a $2.70 stop over a mid-term (45 trading days) horizon.
Eli Lilly's Q1 performance and the retatrutide clinical headline put the company in a class of its own. The stock is trading at $931.64 with a market cap near $880B, rich multiples but justified by blockbuster growth prospects and strong cash generation. This is a position trade: buy at market, stop at $870, target $1,100 over the next 180 trading …
FTAI Aviation ($FTAI) is firing on multiple cylinders: a growing engine leasing and MRO footprint, an expanding feedstock pipeline from recent Air France deals, and promising unit-conversion growth through FTAI Power and data-center partnerships. The stock is richly valued, but current upside is supported by concrete business drivers. We lay out a …
Anika Therapeutics ($ANIK) has pulled back from recent highs after a clinical setback and related investor investigations. The stock is trading at $12.46 with a market cap of roughly $166M and an enterprise value near $147M, while free cash flow remains positive. Technicals show oversold momentum and elevated short interest, creating a favorable ri…
Carlyle (CG) looks like a re-rating candidate trading near $49.60 with a market cap around $17-18 billion, $1.48 billion in trailing free cash flow and a conservative balance sheet (debt/equity ~0.52). Recent deal activity - a planned majority purchase of MAI (03/31/2026) and a conditional Lukoil asset bid (01/31/2026) - supports an earnings/AUM re…
CoreWeave (CRWV) has been repriced by headline-driven volatility even as fundamentals and capacity expansion point to sustained upside. Market cap sits near $62.4B while the company scales GPU capacity and consensus growth trajectories remain aggressive. This trade targets a rebound to $155 over the next 45 trading days with a tight structural stop…
Twenty One Capital (XXI) is a newly formed Bitcoin treasury vehicle whose stock has drawn regulatory scrutiny and rising short activity. With a $5.15B market cap, elevated short volume and a recent shareholder litigation probe, we lay out a mid-term (45 trading days) short trade: entry $7.90, target $5.80, stop $10.50. The trade is high risk but of…
BlackSky (BKSY) is trading at $34 after a run-up driven by government awards and the rollout of higher-resolution Gen-3 satellites. The business is unprofitable today, but near-term revenue visibility has improved through a $99M multi-year IDIQ and a nearly $30M one-year Assured subscription. This trade idea outlines a long entry at $34 with a $42.…
Microsoft is spending big to solve a real constraint: available AI capacity. With Azure growth north of 40%, an AI ARR of $37B and $627B of commercial remaining performance obligations, the $190B capex plan looks demand-driven. This trade plan buys the gap between short-term capex anxiety and longer-term revenue realization.
SoFi (SOFI) is currently trading well below its 52-week high after a headline-driven selloff. Fundamentals still show growing revenue and improving profitability, while leverage is modest and short interest is elevated but manageable. This trade idea lays out an actionable long trade with clear entry, stop and target for a 180 trading-day rebound.
Meta is trading at one of the lowest multiples among the MAG7 group while generating strong free cash flow and returns on equity. With a current price near $670, meaningful downside support at the March low and upside back to the 52-week high, this trade targets a mid-term re-rating over the next 45 trading days while keeping risk defined with a ti…
IREN has pivoted from Bitcoin mining to large-scale, renewable-powered AI and GPU cloud operations. The company already shows scale with a $9.7B Microsoft deal and is on pace for roughly $3.4B in annualized revenue. The market is pricing growth richly, but near-term catalysts and constrained industry capacity create a tactical opportunity. This tra…
<p>Oracle is trading near $160 while sitting on what management and industry reports call a roughly $553 billion backlog of contracted revenue. That backlog isn't just a headline - it's an earnings runway that can materially de-risk growth and justify a higher multiple if conversion and margin expansion continue. Today the market is fixated on near…
Vulcan Materials (VMC) is the largest producer of construction aggregates in the U.S., trading at about $296 per share with a $38.6B market cap. Fundamentals show solid cash generation, a rising dividend and improving technicals. I am initiating a position-sized long at $296.04 with a $330 target and a $270 stop loss over a position horizon (180 tr…
